Hepion said Chief Executive Officer Kaouthar Lbiati resigned for personal reasons, effective immediately. The board appointed Gary Stetz as interim chief executive officer and a director. Vincent LoPriore was appointed executive chairman. Sireesh Appajosyula and Chase LoPriore were appointed directors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hepion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-011222), on March 18, 2026, and is solely responsible for the information contained therein.
Comments